REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results